Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC).
These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine.
Written by:
Van Allen EM, Pomerantz M. Are you the author?
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; The Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):483-90.
doi: 10.1016/j.ucl.2012.07.005
PubMed Abstract
PMID: 23084525
UroToday.com Prostate Cancer Section
